Charles Swanton

109.3k total citations · 23 hit papers
325 papers, 30.6k citations indexed

About

Charles Swanton is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, Charles Swanton has authored 325 papers receiving a total of 30.6k indexed citations (citations by other indexed papers that have themselves been cited), including 175 papers in Cancer Research, 145 papers in Oncology and 132 papers in Molecular Biology. Recurrent topics in Charles Swanton's work include Cancer Genomics and Diagnostics (166 papers), Lung Cancer Treatments and Mutations (49 papers) and Cancer Immunotherapy and Biomarkers (34 papers). Charles Swanton is often cited by papers focused on Cancer Genomics and Diagnostics (166 papers), Lung Cancer Treatments and Mutations (49 papers) and Cancer Immunotherapy and Biomarkers (34 papers). Charles Swanton collaborates with scholars based in United Kingdom, United States and Denmark. Charles Swanton's co-authors include Nicholas McGranahan, Rebecca A. Burrell, Samra Turajlic, Jiří Bártek, Nicolai J. Birkbak, Sergio A. Quezada, Lajos Pusztai, Marco Gerlinger, James Larkin and Solange Peters and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Charles Swanton

312 papers receiving 30.2k citations

Hit Papers

Development of tumor muta... 2009 2026 2014 2020 2018 2017 2017 2013 2019 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
    2018 1.8k citations Charles Swanton, Sergio A. Quezada et al. Annals of Oncology profile →
  2. Renal cell carcinoma
    2017 1.8k citations Charles Swanton et al. profile →
  3. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
    2017 1.8k citations Nicholas McGranahan, Charles Swanton Cell profile →
  4. The causes and consequences of genetic heterogeneity in cancer evolution
    2013 1.6k citations Rebecca A. Burrell, Nicholas McGranahan et al. profile →
  5. Artificial intelligence in cancer imaging: Clinical challenges and applications
    2019 1.2k citations Nicolai J. Birkbak, Charles Swanton et al. profile →
  6. Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution
    2015 765 citations Nicholas McGranahan, Charles Swanton profile →
  7. Cancer heterogeneity: implications for targeted therapeutics
    2013 717 citations Charles Swanton et al. profile →
  8. Intratumor Heterogeneity: Evolution through Space and Time
    2012 672 citations Charles Swanton Cancer Research profile →
  9. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
    2017 662 citations Rachel Rosenthal, Nicholas McGranahan et al. profile →
  10. deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution
    2016 630 citations Rachel Rosenthal, Nicholas McGranahan et al. profile →
  11. Genetic prognostic and predictive markers in colorectal cancer
    2009 529 citations Axel Walther, Charles Swanton et al. profile →
  12. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set
    2021 520 citations Charles Swanton et al. Annals of Oncology profile →
  13. Metastasis as an evolutionary process
    2016 462 citations Charles Swanton et al. profile →
  14. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution
    2015 432 citations Nicholas McGranahan, Nicolai J. Birkbak et al. profile →
  15. Clinical management of breast cancer heterogeneity
    2015 426 citations Charles Swanton et al. profile →
  16. Resolving genetic heterogeneity in cancer
    2019 407 citations Charles Swanton et al. profile →
  17. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
    2018 391 citations Charlotte K.Y. Ng, Charles Swanton et al. Annals of Oncology profile →
  18. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
    2019 383 citations Funda Meric‐Bernstam, Herbert I. Hurwitz et al. profile →
  19. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers
    2019 372 citations Nicolai J. Birkbak, Charles Swanton et al. Annals of Oncology profile →
  20. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
    2018 357 citations John D. Hainsworth, Funda Meric‐Bernstam et al. Journal of Clinical Oncology profile →
  21. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
    2021 251 citations Razelle Kurzrock, John D. Hainsworth et al. profile →
  22. Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
    2024 235 citations Maise Al Bakir, Charles Swanton et al. Cell profile →
  23. Why do patients with cancer die?
    2024 43 citations Mariam Jamal‐Hanjani, Charles Swanton et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Charles Swanton 13.0k 12.8k 12.7k 8.5k 3.4k 325 30.6k
Carsten Denkert 11.5k 0.9× 15.3k 1.2× 11.3k 0.9× 4.4k 0.5× 3.2k 0.9× 522 29.5k
Ming‐Sound Tsao 16.5k 1.3× 15.3k 1.2× 8.3k 0.7× 13.8k 1.6× 2.4k 0.7× 653 37.2k
Jonas Bergh 11.2k 0.9× 15.6k 1.2× 11.6k 0.9× 4.9k 0.6× 2.8k 0.8× 521 29.1k
Ignacio I. Wistuba 16.8k 1.3× 16.4k 1.3× 9.0k 0.7× 12.4k 1.5× 2.7k 0.8× 687 36.0k
Guido Sauter 17.6k 1.4× 13.6k 1.1× 8.1k 0.6× 10.0k 1.2× 2.8k 0.8× 600 35.0k
Lajos Pusztai 12.1k 0.9× 20.1k 1.6× 16.9k 1.3× 5.7k 0.7× 4.2k 1.2× 591 35.0k
Stephen B. Fox 14.2k 1.1× 13.0k 1.0× 10.4k 0.8× 4.7k 0.6× 2.8k 0.8× 423 29.3k
Fabrice André 13.9k 1.1× 20.5k 1.6× 14.1k 1.1× 13.0k 1.5× 3.3k 1.0× 675 38.0k
Jeffrey S. Ross 10.3k 0.8× 15.0k 1.2× 9.1k 0.7× 8.6k 1.0× 4.2k 1.2× 680 28.7k
Richard S. Finn 9.0k 0.7× 16.3k 1.3× 8.3k 0.7× 11.6k 1.4× 4.6k 1.3× 370 38.2k

Countries citing papers authored by Charles Swanton

Since Specialization
Citations

This map shows the geographic impact of Charles Swanton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Swanton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Swanton more than expected).

Fields of papers citing papers by Charles Swanton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Swanton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Swanton. The network helps show where Charles Swanton may publish in the future.

Co-authorship network of co-authors of Charles Swanton

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Swanton. A scholar is included among the top collaborators of Charles Swanton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Swanton. Charles Swanton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Noorani, Imran, et al.. (2025). Extrachromosomal DNA: shaping the evolutionary dynamics of cancer. Trends in cancer. 11(9). 901–916. 1 indexed citations
2.
Weeden, Clare E., et al.. (2024). An agent-based modelling framework to study growth mechanisms in EGFR-L858R mutant cell alveolar type II cells. Royal Society Open Science. 11(7). 240413–240413. 2 indexed citations
3.
Linch, Mark, Gianmarco Leone, Yien Ning Sophia Wong, et al.. (2024). Nivolumab and ipilimumab for metastatic prostate cancer with an immunogenic signature: The NEPTUNES multi-centre two-cohort, biomarker-selected phase 2 trial.. Journal of Clinical Oncology. 42(16_suppl). 5013–5013. 5 indexed citations
4.
Black, James R., Alexander M. Frankell, Selvaraju Veeriah, et al.. (2023). LBA55 An ultra-sensitive and specific ctDNA assay provides novel pre-operative disease stratification in early stage lung cancer. Annals of Oncology. 34. S1294–S1294. 6 indexed citations
5.
Weeden, Clare E., William Hill, Emilia L. Lim, Eva Grönroos, & Charles Swanton. (2023). Impact of risk factors on early cancer evolution. Cell. 186(8). 1541–1563. 61 indexed citations
6.
Chokshi, Chirayu, Agata Kieliszek, Nazanin Tatari, et al.. (2023). An HLA-G/SPAG9/STAT3 axis promotes brain metastases. Proceedings of the National Academy of Sciences. 120(8). e2205247120–e2205247120. 8 indexed citations
7.
Friedman, Claire F., John D. Hainsworth, Razelle Kurzrock, et al.. (2021). Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. Cancer Discovery. 12(3). 654–669. 56 indexed citations
8.
Hainsworth, John D., Funda Meric‐Bernstam, Charles Swanton, et al.. (2018). Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. Journal of Clinical Oncology. 36(6). 536–542. 357 indexed citations breakdown →
9.
Venkatesan, Subramanian, Rachel Rosenthal, Nnennaya Kanu, et al.. (2018). APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution. UCL Discovery (University College London). 1 indexed citations
10.
Sansregret, Laurent, James O. Patterson, Sally M. Dewhurst, et al.. (2017). APC/C Dysfunction Limits Excessive Cancer Chromosomal Instability. Cancer Discovery. 7(2). 218–233. 80 indexed citations
11.
Domingues, Patrícia H., Lalitha S.Y. Nanduri, Cristina Viganó, et al.. (2017). Cellular Prion Protein PrPC and Ecto-5′-Nucleotidase Are Markers of the Cellular Stress Response to Aneuploidy. Cancer Research. 77(11). 2914–2926. 8 indexed citations
12.
Murugaesu, Nirupa, Gareth A. Wilson, Nicolai J. Birkbak, et al.. (2015). Tracking the Genomic Evolution of Esophageal Adenocarcinoma through Neoadjuvant Chemotherapy. Cancer Discovery. 5(8). 821–831. 178 indexed citations
13.
Dewhurst, Sally M., Nicholas McGranahan, Rebecca A. Burrell, et al.. (2014). Tolerance of Whole-Genome Doubling Propagates Chromosomal Instability and Accelerates Cancer Genome Evolution. Cancer Discovery. 4(2). 175–185. 287 indexed citations
14.
Gaykema, Sietske B.M., Carolien P. Schröder, Joanna Vitfell-Rasmussen, et al.. (2014). 89Zr-trastuzumab and 89Zr-bevacizumab PET to Evaluate the Effect of the HSP90 Inhibitor NVP-AUY922 in Metastatic Breast Cancer Patients. Clinical Cancer Research. 20(15). 3945–3954. 95 indexed citations
15.
Endesfelder, David, Rebecca A. Burrell, Nnennaya Kanu, et al.. (2014). Chromosomal Instability Selects Gene Copy-Number Variants Encoding Core Regulators of Proliferation in ER+ Breast Cancer. Cancer Research. 74(17). 4853–4863. 47 indexed citations
16.
Ng, Charlotte K.Y., Britta Weigelt, Roger A’Hern, et al.. (2014). Predictive Performance of Microarray Gene Signatures: Impact of Tumor Heterogeneity and Multiple Mechanisms of Drug Resistance. Cancer Research. 74(11). 2946–2961. 15 indexed citations
17.
Birkbak, Nicolai J., Aron C. Eklund, Qiyuan Li, et al.. (2011). Paradoxical Relationship between Chromosomal Instability and Survival Outcome in Cancer. Cancer Research. 71(10). 3447–3452. 258 indexed citations
18.
Roylance, Rebecca, David Endesfelder, Patricia Gorman, et al.. (2011). Relationship of Extreme Chromosomal Instability with Long-term Survival in a Retrospective Analysis of Primary Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. 20(10). 2183–2194. 133 indexed citations
19.
Lee, Alvin, David Endesfelder, Andrew J. Rowan, et al.. (2011). Chromosomal Instability Confers Intrinsic Multidrug Resistance. Cancer Research. 71(5). 1858–1870. 358 indexed citations
20.
McKeen, Hayley D., Christopher Byrne, Puthen V. Jithesh, et al.. (2010). FKBPL Regulates Estrogen Receptor Signaling and Determines Response to Endocrine Therapy. Cancer Research. 70(3). 1090–1100. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carsten Denkert Breakdown of academic impact, for papers by Ming‐Sound Tsao Breakdown of academic impact, for papers by Jonas Bergh Breakdown of academic impact, for papers by Ignacio I. Wistuba Breakdown of academic impact, for papers by Guido Sauter Breakdown of academic impact, for papers by Lajos Pusztai Breakdown of academic impact, for papers by Stephen B. Fox Breakdown of academic impact, for papers by Fabrice André Breakdown of academic impact, for papers by Jeffrey S. Ross Breakdown of academic impact, for papers by Richard S. Finn
Rankless by CCL
2026